IDEXX Stock Soars 17%, Adding $7.5 Billion, After Raising 2026 Revenue And Earnings Outlook

The pet-diagnostics company lifted its yearly outlook but trimmed its operating margin target, and its shares jumped in Monday trading.

Share
IDEXX Stock Soars 17%, Adding $7.5 Billion, After Raising 2026 Revenue And Earnings Outlook

IDEXX Laboratories, which makes diagnostic tools for veterinarians, saw its shares climb 17.29% to $646.51 in Monday trading, as of 9:45 a.m. ET, adding about $7.5 billion in market value. The move followed third-quarter results and a higher full-year outlook, detailed in an 8-K filed that day.

Higher guide, slightly lower margin

The full-year forecast now calls for revenue of $4,741 million–$4,767 million. Earnings per share are guided to $14.96–$15.16. The quarter brought $1,214 million in revenue, with diluted EPS of $4.01, up 18% as reported.

The operating margin target slipped to 32.1%–32.3%, from 32.3%–32.5%.

Recurring revenue in the diagnostics business rose 11%. Installed analyzers are nearly 11,000.

A long slide, partly recovered

IDEXX develops and sells diagnostic products and services, mainly for veterinary clinics, livestock, poultry and dairy producers, and water testing. Its largest unit, the Companion Animal Group, sells in-clinic analyzers, rapid test kits, reference laboratory testing, and practice management and imaging software.

At Friday's close, October 30, the shares were down about 18% for the year, while the S&P 500 was up about 11%. The stock closed that day 28% below its highest close of the past year, set on November 25, 2025, so Monday's jump recovers only part of the decline.

The stock was on pace for its biggest one-day gain in at least 274 trading sessions, the first since September 30, 2025. At Monday's intraday price, IDEXX's total market value was $50.9 billion.

In its prior quarterly filing, the company reported revenue of $1.2 billion, up 9.7% from a year earlier, with net income of $338.4 million.

Monday's price of $646.51 still left the stock well short of its year-ago peak, with the S&P 500 up about 11% this year against IDEXX's roughly 18% decline as of Friday's close.

Sources

More on IDEXX Laboratories

All IDEXX Laboratories (IDXX) coverage →